Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
Agresti R, Crippa F, Sandri M, Martelli G, Tagliabue E, Alessi A, Pellitteri C, Maccauro M, Maugeri I, Barbara P, Rampa M, Moscaroli A, Ferraris C, Carcangiu ML, Bianchi G, Greco M, Bombardieri E. Agresti R, et al. Among authors: bombardieri e. Breast. 2014 Aug;23(4):334-40. doi: 10.1016/j.breast.2014.01.001. Epub 2014 Jan 31. Breast. 2014. PMID: 24485802 Free article.
FDG-PET in thyroid cancer.
Crippa F, Alessi A, Gerali A, Bombardieri E. Crippa F, et al. Among authors: bombardieri e. Tumori. 2003 Sep-Oct;89(5):540-3. doi: 10.1177/030089160308900517. Tumori. 2003. PMID: 14870781 Review.
FDG-PET for axillary lymph node staging in primary breast cancer.
Crippa F, Gerali A, Alessi A, Agresti R, Bombardieri E. Crippa F, et al. Among authors: bombardieri e. Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S97-102. doi: 10.1007/s00259-004-1531-z. Epub 2004 May 5. Eur J Nucl Med Mol Imaging. 2004. PMID: 15133635 Review.
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.
Crippa F, Agresti R, Sandri M, Mariani G, Padovano B, Alessi A, Bianchi G, Bombardieri E, Maugeri I, Rampa M, Carcangiu ML, Trecate G, Pascali C, Bogni A, Martelli G, de Braud F. Crippa F, et al. Among authors: bombardieri e. Eur J Nucl Med Mol Imaging. 2015 May;42(6):818-30. doi: 10.1007/s00259-015-2995-8. Epub 2015 Feb 12. Eur J Nucl Med Mol Imaging. 2015. PMID: 25673053
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R, Micheli A, Asero S, Ferraris C, Gennaro M, Bombardieri E, Cascinelli N. Greco M, et al. Among authors: bombardieri e. J Natl Cancer Inst. 2001 Apr 18;93(8):630-5. doi: 10.1093/jnci/93.8.630. J Natl Cancer Inst. 2001. PMID: 11309439 Clinical Trial.
PET imaging in breast cancer.
Bombardieri E, Crippa F. Bombardieri E, et al. Q J Nucl Med. 2001 Sep;45(3):245-56. Q J Nucl Med. 2001. PMID: 11788817 Review.
Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
Bampo C, Alessi A, Fantini S, Bertarelli G, de Braud F, Bombardieri E, Valvo F, Crippa F, Di Bartolomeo M, Mariani L, Milione M, Biondani P, Avuzzi B, Chiruzzi C, Pietrantonio F. Bampo C, et al. Among authors: bombardieri e. Oncology. 2013;84(4):191-9. doi: 10.1159/000345601. Epub 2013 Jan 15. Oncology. 2013. PMID: 23328390 Clinical Trial.
318 results